<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904653</url>
  </required_header>
  <id_info>
    <org_study_id>HVST-HEMO-20</org_study_id>
    <nct_id>NCT04904653</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage</brief_title>
  <official_title>Randomized Controlled and Single Blind Clinical Trial in Women With Breast Cancer and Axillary Lymphadenectomy, to Evaluate the Effectiveness of Hemopatch® in the Reduction of Post-surgical Serous Drainage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ASOCIACION DE CIRUJANOS DE MAMA DE TOLEDO, PASEO MIRADERO S/N, PALACIO DE CONGRESOS, 45001, TOLEDO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemopatch is an alternative to reduce morbidity associated with axillary lymphadenectomy&#xD;
      surgery, possibly contributing to improved patient management, clinical outcomes, and&#xD;
      hospital costs. We propose a multicenter, controlled, and randomized trial to study the&#xD;
      efficacy of Hemopatch in reducing serous wound drainage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After axillary node dissection, patients will be randomised to:&#xD;
Hemopatch Group: Hemopatch (hemostatic device and surgical sealant) + suction drainage&#xD;
Control group: no sealant (liquid, gel or patch) + suction drain</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume in milliliters (ml) of drainage</measure>
    <time_frame>In the last 24 hours</time_frame>
    <description>Total volume in milliliters (ml) of drainage: To be measured in the hospital every day before discharge, and collected daily after discharge with a follow-up of phone calls or patient diaries during hospital visits until extraction drain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Hemopatch</condition>
  <condition>Breast Cancer</condition>
  <condition>Axillary Lymphadenectomy</condition>
  <arm_group>
    <arm_group_label>Hemopatch Group:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemopatch + suction drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No sealant (liquid, gel or patch) + suction drain</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemopatch</intervention_name>
    <description>HEMOPATCH Sealing Hemostat (&quot;HEMOPATCH&quot;) consists of a soft, thin, pliable, flexible pad of collagen derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate).&#xD;
Due to its flexible structure, the application of HEMOPATCH to the site where hemostasis / sealing is desired is easily controlled. For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.&#xD;
HEMOPATCH is supplied in the following 3 sizes:&#xD;
HEMOPATCH 27 x 27 mm&#xD;
HEMOPATCH 45 x 45 mm&#xD;
HEMOPATCH 45 x 90 mm</description>
    <arm_group_label>Hemopatch Group:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>No sealant (liquid, gel or patch) + suction drain</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Preoperative:&#xD;
&#xD;
          -  Female gender&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Breast cancer N+&#xD;
&#xD;
          -  Conservative Surgery: Lumpectomy or Quadrantectomy&#xD;
&#xD;
          -  Berg levels 1-2 axillary lymphadenectomy&#xD;
&#xD;
        Intraoperative:&#xD;
&#xD;
          -  Axillary incision separated from the incision for the breast lesion&#xD;
&#xD;
          -  Placement of a closed low pressure suction drain in the axillary fossa&#xD;
&#xD;
          -  Hemostasis and lymphostasis using clips, electrocautery, electric scalpel or bipolar&#xD;
             coagulation&#xD;
&#xD;
        Postoperative:&#xD;
&#xD;
        - Patients with ≥ 10 axillary nodes removed&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Preoperative:&#xD;
&#xD;
          -  Mastectomy&#xD;
&#xD;
          -  Previous radiation therapy&#xD;
&#xD;
          -  Previous axillary emptying&#xD;
&#xD;
          -  Liver pathology&#xD;
&#xD;
          -  Diabetic decompensation: defined as any episode that has required medical attention in&#xD;
             an emergency service or hospital admission; and also that which has required a&#xD;
             modification of the patient's drugs, or an increase of more than 20% of the total&#xD;
             daily dose.&#xD;
&#xD;
          -  Known allergies to any component of Hemopatch (proteins of bovine origin or PEG)&#xD;
&#xD;
          -  Psychiatric disorder that conditions the non-understanding of the questionnaire, or&#xD;
             incapacitation of the patient to understand it&#xD;
&#xD;
          -  Simultaneous participation in another clinical study&#xD;
&#xD;
          -  PCR positive for SARS-CoV-2&#xD;
&#xD;
        Intraoperative:&#xD;
&#xD;
          -  Level 3 axillary dissection (severe axillary involvement)&#xD;
&#xD;
          -  Unexpected surgical contraindication&#xD;
&#xD;
          -  Hemostasis and lymphostasis: ultrasonic techniques or other advanced energy techniques&#xD;
             are excluded.&#xD;
&#xD;
          -  Use of fibrin sealants (eg: Tisseel, Artiss, Tachosil), cyanoacrylate type adhesives&#xD;
             (eg: Glubran-2) or other types of products (oxidized cellulose format, powders or&#xD;
             gelatin sheets or collagen).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>María García Ávila, MD</last_name>
    <phone>638432910</phone>
    <email>garciaavilamaria@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Surgery and Digestive System Service</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Justo Álvarez Martín, MD</last_name>
      <email>justoam66@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

